<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409926</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078692</org_study_id>
    <nct_id>NCT03409926</nct_id>
  </id_info>
  <brief_title>The Need for FibEr Addition in SympTomatic Heart Failure</brief_title>
  <acronym>FEAST-HF</acronym>
  <official_title>The Need for FibEr Addition in SympTomatic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FEAST-HF is a single-centre clinical trial in ambulatory patients with chronic HF to evaluate
      whether dietary supplementation with acacia gum reduces HF-related biomarkers NT-proBNP and
      ST2 and how the gut microbiome responds to dietary supplementation with acacia gum. The
      hypotheses of this study are 1) that changes in the gut microbiome will be correlated with a
      reduction in NT-proBNP and ST2 in patients with HF after treatment with acacia gum, and 2)
      gut microbiome configurations (composition, diversity), stability and function (gene content)
      will be significantly altered in patients with HF in response to acacia gum.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in NT-proBNP level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST2</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in NT-proBNP level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Clinical Outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>All cause death, hospitalizations and emergency department visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in quality of life assessed by the Kansas City Cardiomyopathy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in NYHA class treated as a categorical variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in 6-Minute Walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Microbiome Characterization</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>To examine the gut microbiome in a descriptive manner and characterize predominant species and those linked to Short Chain Fatty Acid production</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Microcrystalline Cellulose (MCC) 10 grams/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-fermentable active control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acacia Gum 5 grams/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fermentable dietary fiber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acacia Gum 10 grams/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fermentable dietary fiber</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acacia Gum</intervention_name>
    <description>dietary supplement will be added to the participant's usual diet</description>
    <arm_group_label>Microcrystalline Cellulose (MCC) 10 grams/day</arm_group_label>
    <arm_group_label>Acacia Gum 5 grams/day</arm_group_label>
    <arm_group_label>Acacia Gum 10 grams/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Willing and able to provide informed consent

          -  Patients with established Heart Failure (as per their treating physician) including
             those with both reduced and preserved ejection fraction

        Exclusion Criteria:

          -  Patients requiring a special diet that would prohibit the intervention (e.g. celiac
             disease, irritable bowel disease)

          -  Patients who do not control their own meals (e.g. meals-on-wheels, long-term care)

          -  Patients with conditions that would interfere with the analysis of the microbiome
             (e.g. chronic diarrhea, recent antibiotics within the past month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Ezekowitz, MBBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Ezekowitz, MBBCh</last_name>
    <phone>780-407-8719</phone>
    <email>feasthf@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Kushniruk, RN, PhD</last_name>
    <email>feasthf@ualberta.ca</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Justin Ezekowitz</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Diet</keyword>
  <keyword>Fiber</keyword>
  <keyword>Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

